Drug-eluting stents beat bare-metal stents when used off-label, says study
This article was originally published in Clinica
A study of the off-label use of drug-eluting stents (DESs) shows that the devices do not carry an increased risk of death compared to bare-metal stents (BMSs).
You may also be interested in...
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.
Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.